[SP3] Scientific Platform 3: Epilepsy A & B

[SP3-3A-1] Evolution of EEG Findings in Patients with Intractable Partial Epilepsy Successfully Treated by Pranlukast

^○Ayemu SAAN^{1, 2} (1.National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders NHO, Japan, 2.Yangon Children Hospital, Yangon, Myanmar)

Pranlukast was reported to be effective for intractable partial seizures, but the effect on epileptic discharges has not been documented. To evaluate the therapeutic effect of pranlukast, evolution of Electroencephalography (EEG) findings has to be studied. We retrospectively reviewed serial EEGs recorded before and after pranlukast treatment in seven patients who became seizure-free after treatment with pranlukast. The age of epilepsy onset ranged from 3 months to 6 years. Four patients had frontal lobe epilepsy, and three had occipital lobe epilepsy. Before pranlukast treatment, seizure frequency was daily in six and weekly in one patient. The starting dose of pranlukast ranged from 3.8 to 8.6 mg/kg/day, and the maintenance dose from 7.2 to 10.7 mg/kg/day. At the last follow-up of six patients, background activity on EEGs improved in two patients and was unchanged in four. On awake EEGs, remarkable interictal discharges (IIDs) were consistently absent in one patient, while IIDs were unchanged in two patients and aggravated in three patients compared to before pranlukast add-on. On asleep EEGs, remarkable IIDs were consistently absent in one patient, while IIDs improved in five patients, and were unchanged in two patients who started pranlukast at an older age, compared to before pranlukast add-on. Our data suggest the following sequence of improvement after starting pranlukast treatment: improvement of IIDs on asleep EEG, followed by cessation of seizures, and subsequently improvement of background activity on EEG. Background activity and IIDs during sleep may reflect the effect of pranlukast on seizure outcome.